Identification of predictive factors of response to the BH3‐mimetic molecule ABT‐737: An ex vivo experiment in human serous ovarian carcinoma

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0215|136|5|E340-E350

ISSN： 0020-7136

Source： INTERNATIONAL JOURNAL OF CANCER, Vol.136, Iss.5, 2015-03, pp. : E340-E350

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PI3K inhibitor GDC-0941 enhances apoptotic effects of BH-3 mimetic ABT-737 in AML cells in the hypoxic bone marrow microenvironment

By Jin Linhua   Tabe Yoko   Kojima Kensuke   Shikami Masato   Benito Juliana   Ruvolo Vivian   Wang Rui-Yu   McQueen Teresa   Ciurea Stefan   Miida Takashi   Andreeff Michael   Konopleva Marina  

Journal of Molecular Medicine, Vol. 91, Iss. 12, 2013-12 ,pp. : 1383-1397

Springer Publishing Company

Access to resources Recommend Favorite

Alteration in PI3K/mTOR, MAPK pathways and Her2 expression/amplification is more frequent in uterine serous carcinoma than ovarian serous carcinoma

By  

JOURNAL OF SURGICAL ONCOLOGY, Vol. 112, Iss. 2, 2015-08 ,pp. : 188-194

John Wiley & Sons Inc

Access to resources Recommend Favorite

Prognostic Factors of Secondary Ovarian Carcinoma

By  

Oncology, Vol. 63, Iss. 2, 2002-09 ,pp. : 124-129

Karger

Access to resources Recommend Favorite

BH3‐domain mimetic compound BH3I‐2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 121, Iss. 2, 2003-04 ,pp. : 332-340

John Wiley & Sons Inc

Access to resources Recommend Favorite

GATA3: A promising marker for metastatic breast carcinoma in serous effusion specimens

By  

CANCER CYTOPATHOLOGY, Vol. 122, Iss. 4, 2014-04 ,pp. : 307-312

John Wiley & Sons Inc

Access to resources Recommend Favorite